#pfizer

#pfizer

After leading Pfizer through the frantic race to develop the first FDA-approved COVID-19 vaccine, CEO Albert Bourla has set his sights on a new, arguably more difficult moonshot. "We saved the world from Covid, now we'll save the world from cancer," Bourla told Fortune Editor-in-Chief Alyson Shontell, outlining the company's massive pivot toward oncology following the pandemic. This ambition is backed by a historic reallocation of capital.

Pfizer beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. The stock gapped up roughly 12.6% in pre-market trading, reflecting strong investor validation of both the beat and the company's reaffirmed full-year guidance paired with a raised EPS outlook. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion but raised EPS guidance to $3.00 to $3.15 from prior guidance.

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood ( NASDAQ:HOOD ) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday people to build portfolios without needing thousands upfront. But that doesn't mean buying cheap stocks is always a good idea, since a low price could signal company problems - and certainly steer clear of penny stocks, which carry high risks of fraud and volatility. Sometimes, though, a low share price signals real opportunity.

Pfizer is the first big pharmaceutical company to reach an agreement with the Trump administration over most-favored nation drug pricing, a deal that lowers U.S. prices of certain medications and makes them available directly to patients through new online channels. The agreement announced Tuesday also gives Pfizer a grace period before facing potential tariffs on its drugs. With most-favored nation pricing, the prices of a drug in the U.S. will be matched to the lowest price of the same drug in a comparable developed nation.

Pfizer's Covid vaccine for young children may not be renewed by the FDA this fall, leading to a gap in available vaccines for those under five.

Part of moving biddable marketing channels in-house is having a deeper understanding of the brand. At an agency, the focus can often be diluted across various clients.

HII Mission Technologies earns approximately $4.5 billion annually, accounting for 1% of all DoD contract spending by developing unmanned underwater vehicles and drones for naval missions.

Pfizer's decision to halt danuglipron development underscores the risks and complexities involved in creating new obesity treatments, particularly after significant financial investment and testing phases.